company background image
LUN

H. Lundbeck CPSE:LUN Stock Report

Last Price

kr.172.70

Market Cap

kr.34.3b

7D

5.1%

1Y

-10.8%

Updated

10 Jun, 2022

Data

Company Financials +
LUN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance0/6
Financial Health5/6
Dividends0/6

LUN Stock Overview

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally.

H. Lundbeck Competitors

Price History & Performance

Summary of all time highs, changes and price drops for H. Lundbeck
Historical stock prices
Current Share Pricekr.172.70
52 Week Highkr.207.30
52 Week Lowkr.142.60
Beta0.61
1 Month Change8.28%
3 Month Change7.94%
1 Year Change-10.77%
3 Year Change-31.98%
5 Year Change-52.65%
Change since IPO246.96%

Recent News & Updates

Shareholder Returns

LUNDK PharmaceuticalsDK Market
7D5.1%4.3%4.1%
1Y-10.8%10.8%-0.4%

Return vs Industry: LUN underperformed the Danish Pharmaceuticals industry which returned 6.9% over the past year.

Return vs Market: LUN underperformed the Danish Market which returned -2.8% over the past year.

Price Volatility

Is LUN's price volatile compared to industry and market?
LUN volatility
LUN Average Weekly Movement5.0%
Pharmaceuticals Industry Average Movement5.6%
Market Average Movement6.4%
10% most volatile stocks in DK Market10.9%
10% least volatile stocks in DK Market3.5%

Stable Share Price: LUN is not significantly more volatile than the rest of Danish stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: LUN's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19155,353Deborah Dunsirehttps://www.lundbeck.com

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company’s principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer’s disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington’s disease, as well as other products.

H. Lundbeck Fundamentals Summary

How do H. Lundbeck's earnings and revenue compare to its market cap?
LUN fundamental statistics
Market Capkr.34.31b
Earnings (TTM)kr.1.11b
Revenue (TTM)kr.16.40b

0.0x

P/E Ratio

0.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LUN income statement (TTM)
Revenuekr.16.40b
Cost of Revenuekr.3.51b
Gross Profitkr.12.89b
Other Expenseskr.11.78b
Earningskr.1.11b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 17, 2022

Earnings per share (EPS)5.58
Gross Margin78.59%
Net Profit Margin6.76%
Debt/Equity Ratio32.2%

How did LUN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is LUN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LUN?

Other financial metrics that can be useful for relative valuation.

LUN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.4x
Enterprise Value/EBITDA10.3x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does LUN's PE Ratio compare to its peers?

LUN PE Ratio vs Peers
The above table shows the PE ratio for LUN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Averagen/a
ALK B ALK-Abelló
108.6x39.7%kr.27.7b
NOVO B Novo Nordisk
35.6x14.0%kr.1.8t
CHEMM ChemoMetec
102.9xn/akr.14.0b
ORNBV Orion Oyj
28.9x13.7%€5.5b
LUN H. Lundbeck
n/a26.1%kr.34.3b

Price-To-Earnings vs Peers: Insufficient data to calculate LUN's Price-To-Earnings Ratio vs. peers for valuation analysis.


Price to Earnings Ratio vs Industry

How does LUN's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

Price-To-Earnings vs Industry: Insufficient data to calculate LUN's Price-To-Earnings Ratio vs. industry for valuation analysis.


Price to Earnings Ratio vs Fair Ratio

What is LUN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LUN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ration/a
Fair PE Ratio29.7x

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate LUN's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of LUN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: LUN (DKK172.7) is trading below our estimate of fair value (DKK558.6)

Significantly Below Fair Value: LUN is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LUN's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is H. Lundbeck forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?

Future Growth Score

3/6

Future Growth Score 3/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


26.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LUN's forecast earnings growth (26.1% per year) is above the savings rate (0.09%).

Earnings vs Market: LUN's earnings (26.1% per year) are forecast to grow faster than the Danish market (9.4% per year).

High Growth Earnings: LUN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: LUN's revenue (6.3% per year) is forecast to grow slower than the Danish market (6.4% per year).

High Growth Revenue: LUN's revenue (6.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: LUN's Return on Equity is forecast to be low in 3 years time (15.5%).


Discover growth companies

Past Performance

How has H. Lundbeck performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-13.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: LUN has a large one-off loss of DKK702.0M impacting its March 31 2022 financial results.

Growing Profit Margin: LUN's current net profit margins (6.8%) are lower than last year (12.1%).


Past Earnings Growth Analysis

Earnings Trend: LUN's earnings have declined by 13.9% per year over the past 5 years.

Accelerating Growth: LUN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: LUN had negative earnings growth (-47.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (17.9%).


Return on Equity

High ROE: LUN's Return on Equity (6%) is considered low.


Discover strong past performing companies

Financial Health

How is H. Lundbeck's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: LUN's short term assets (DKK9.0B) exceed its short term liabilities (DKK7.8B).

Long Term Liabilities: LUN's short term assets (DKK9.0B) exceed its long term liabilities (DKK8.8B).


Debt to Equity History and Analysis

Debt Level: LUN's net debt to equity ratio (23.5%) is considered satisfactory.

Reducing Debt: LUN's debt to equity ratio has increased from 18% to 32.2% over the past 5 years.

Debt Coverage: LUN's debt is well covered by operating cash flow (33%).

Interest Coverage: LUN's interest payments on its debt are well covered by EBIT (17.2x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is H. Lundbeck current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate LUN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LUN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LUN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LUN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LUN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Deborah Dunsire (59 yo)

3.75yrs

Tenure

kr.56,600,000

Compensation

Dr. Deborah Dunsire, M.D. serves as Director at Syros Pharmaceuticals, Inc. since September 09, 2021. She serves as Chief Executive Officer and President at H. Lundbeck A/S since September 1, 2018 and serv...


CEO Compensation Analysis

Compensation vs Market: Deborah's total compensation ($USD8.01M) is above average for companies of similar size in the Danish market ($USD3.23M).

Compensation vs Earnings: Deborah's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Leadership Team

Experienced Management: LUN's management team is considered experienced (3.3 years average tenure).


Board Members

Experienced Board: LUN's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

H. Lundbeck A/S's employee growth, exchange listings and data sources


Key Information

  • Name: H. Lundbeck A/S
  • Ticker: LUN
  • Exchange: CPSE
  • Founded: 1915
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr.34.306b
  • Shares outstanding: 198.65m
  • Website: https://www.lundbeck.com

Number of Employees


Location

  • H. Lundbeck A/S
  • Ottiliavej 9
  • Valby
  • Capital Region of Denmark
  • 2500
  • Denmark

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/10 00:00
End of Day Share Price2022/06/09 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.